My Bibliography

select

Hallaert P, Roman JW, Baker M, Hill NT, Marte JL, Gulley JL, Logemann N, Hudgens CW, Reuben A, Brownell I. Spontaneous tumor regression and immunotherapy response demonstrate clonal T-cell expansion in Merkel cell carcinoma. NPJ Precis Oncol. 2025 Jul 1;9(1):212. doi: 10.1038/s41698-025-00987-6. PubMed PMID: 40594889; PubMed Central PMCID: PMC12218097.

select

Lassoued W, Madan RA, Xue E, Burnett D, Canubas KD, Bailey S, Marté JL, Tsai YT, Donahue RN, Turkbey IB, Papanicolau-Sengo A, Williams M, Hankin A, Manukyan M, Manu M, Kang Z, Pritchard C, Dahut W, Karzai F, Schlom J, Sater S, Pinto P, Gulley JL. Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer. J Immunother Cancer. 2025 Jun 22;13(6). doi: 10.1136/jitc-2024-010851. PubMed PMID: 40550568; PubMed Central PMCID: PMC12184344.

select

Maldonado MDM, Gracia-Hernandez M, Le LH, Iida M, Gulley JL, Donahue RN, Palena C, Schlom J, Hamilton DH. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control. J Immunother Cancer. 2025 May 13;13(5). doi: 10.1136/jitc-2024-011378. PubMed PMID: 40360436; PubMed Central PMCID: PMC12163335.

select

Awosika JA, Gulley JL, Pastor DM. Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. Int J Mol Sci. 2025 May 6;26(9). doi: 10.3390/ijms26094394. Review. PubMed PMID: 40362635; PubMed Central PMCID: PMC12072705.

select

Poppe LK, Roller N, Medina-Enriquez MM, Lassoued W, Burnett D, Lothstein KE, Khelifa AS, Miyamoto M, Gulley JL, Jochems C, Schlom J, Gameiro SR. Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy. J Immunother Cancer. 2025 May 2;13(5). doi: 10.1136/jitc-2024-011074. PubMed PMID: 40316302; PubMed Central PMCID: PMC12049950.

select

Floudas CS, Goswami M, Donahue RN, Pastor DM, Redman JM, Brownell I, Turkbey EB, Cordes LM, Steinberg SM, Manu M, Francis DC, Lamping E, Marté JL, Kackley M, Krauss E, Manukyan M, Jochems C, Schlom J, Gulley JL, Strauss J. Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Apr 1;11(4):394-399. doi: 10.1001/jamaoncol.2024.6998. PubMed PMID: 39976981; PubMed Central PMCID: PMC11843463.

select

Norberg SM, Valdez J, Napier S, Kenyon M, Ferraro E, Wheatley M, Parsons-Wandell L, Doran SL, Lankford A, Sabzevari H, Brough DE, Schlom J, Gulley JL, Allen CT. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. Lancet Respir Med. 2025 Apr;13(4):318-326. doi: 10.1016/S2213-2600(24)00368-0. Epub 2025 Jan 21. PubMed PMID: 39855244; PubMed Central PMCID: PMC11968209.

select

Floudas CS, Goswami M, Donahue RN, Strauss J, Pastor DM, Redman JM, Brownell I, Turkbey EB, Steinberg SM, Cordes LM, Marté JL, Khan MH, McMahon S, Lamping E, Manu M, Manukyan M, Brough DE, Lankford A, Jochems C, Schlom J, Gulley JL. PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer. Cancer Immunol Immunother. 2025 Mar 21;74(5):155. doi: 10.1007/s00262-025-04009-z. PubMed PMID: 40116923; PubMed Central PMCID: PMC11928712.

select

Redman JM, Donahue RN, Steinberg SJ, Marté JL, Cordes L, Floudas CS, Prins D, Turkbey EB, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection. Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyaf006. PubMed PMID: 40156838; PubMed Central PMCID: PMC11954585.

select

Wang CJ, Strong J, Gatti-Mays ME, Lassoued W, Sater S, Strauss J, Redman JM, Schlom J, Gulley JL, Brownell I. Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammation. Front Immunol. 2025;16:1432927. doi: 10.3389/fimmu.2025.1432927. eCollection 2025. PubMed PMID: 40103819; PubMed Central PMCID: PMC11914793.

select

Zhang L, Troccoli CI, Mateo-Victoriano B, Misiara Lincheta L, Jackson E, Shu P, Plastini T, Tao W, Kwon D, Chen XS, Sharma J, Jorda M, Kumar S, Lombard DB, Gulley JL, Bilusic M, Lockhart AC, Beuve A, Rai P. Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. Cancer Res. 2025 Jan 2;85(1):134-153. doi: 10.1158/0008-5472.CAN-24-0133. PubMed PMID: 39388307; PubMed Central PMCID: PMC11695179.

select

Lim HY, Heo J, Peguero JA, Ryoo BY, Decaens T, Barlesi F, Moehler MH, Jehl G, Eggleton SP, Bajars M, Gulley JL. Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC. Hepatology. 2025 Jan 1;81(1):32-43. doi: 10.1097/HEP.0000000000001054. Epub 2024 Aug 13. PubMed PMID: 39141577; PubMed Central PMCID: PMC11643128.

select

Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024 Dec 10;332(22):1924-1935. doi: 10.1001/jama.2024.19462. Review. PubMed PMID: 39495525; PubMed Central PMCID: PMC11808657.

select

Xue E, Bracken-Clarke D, Krause H, Adeyelu T, Evans MG, Akbulut D, Quezado M, Gandhi N, Farrell A, Soares HP, Lou E, Phan M, Patel R, Vanderwalde AM, Elliott A, Steuer CE, Saba NF, Lubin DJ, London NR Jr, Gulley JL, Floudas CS. Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies. Cancers (Basel). 2024 Nov 24;16(23). doi: 10.3390/cancers16233931. PubMed PMID: 39682120; PubMed Central PMCID: PMC11640466.

select

Zhang L, Norberg SM, Karimipour F, Davies JS, Kuznetsov A, Lassoued W, Burnett D, Homan P, Cam M, Sinkoe A, Xue P, Gulley JL, Hinrichs CS. Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants. J Immunother Cancer. 2024 Nov 18;12(11). doi: 10.1136/jitc-2024-009868. PubMed PMID: 39557544; PubMed Central PMCID: PMC11574437.

select

Larkin RM, Lopez DC, Robbins YL, Lassoued W, Canubas K, Warner A, Karim B, Vulikh K, Hodge JW, Floudas CS, Gulley JL, Gallia GL, Allen CT, London NR Jr. Correction to: Augmentation of tumor expression of HLADR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses. J Transl Med. 2024 Sep 11;22(1):836. doi: 10.1186/s12967-024-05514-y. PubMed PMID: 39261932; PubMed Central PMCID: PMC11391589.

select

Hoang DT, Dinstag G, Shulman ED, Hermida LC, Ben-Zvi DS, Elis E, Caley K, Sammut SJ, Sinha S, Sinha N, Dampier CH, Stossel C, Patil T, Rajan A, Lassoued W, Strauss J, Bailey S, Allen C, Redman J, Beker T, Jiang P, Golan T, Wilkinson S, Sowalsky AG, Pine SR, Caldas C, Gulley JL, Aldape K, Aharonov R, Stone EA, Ruppin E. A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics. Nat Cancer. 2024 Sep;5(9):1305-1317. doi: 10.1038/s43018-024-00793-2. Epub 2024 Jul 3. PubMed PMID: 38961276.

select

Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 Sep 1;42(25):3033-3046. doi: 10.1200/JCO.23.02233. Epub 2024 Jul 2. PubMed PMID: 38954785; PubMed Central PMCID: PMC11361361.

select

Fay M, Sievers C, Robbins Y, Yang X, Huynh A, Redman JM, Hodge JW, Schlom J, Gulley JL, Allen CT, Craveiro M. TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice. iScience. 2024 Aug 16;27(8):110520. doi: 10.1016/j.isci.2024.110520. eCollection 2024 Aug 16. PubMed PMID: 39139402; PubMed Central PMCID: PMC11321305.

select

Gandhy SU, Karzai FH, Bilusic M, McMahon S, Cordes LM, Marte J, Weisman AJ, Perk TG, Lindenberg L, Mena E, Turkbey B, Arlen PM, Dahut WL, Figg WD, Choyke P, Gulley JL, Madan RA. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. Eur Urol Oncol. 2024 Aug;7(4):735-741. doi: 10.1016/j.euo.2023.09.010. Epub 2023 Oct 17. PubMed PMID: 37858437; PubMed Central PMCID: PMC11021375.

select

Schlom J, Donahue RN, Palena C, Gameiro SR, Hodge JW, Hamilton DH, Gulley JL. Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. J Immunother Cancer. 2024 Jul 8;12(7). doi: 10.1136/jitc-2024-009595. PubMed PMID: 38977329; PubMed Central PMCID: PMC11256020.

select

Choradia N, Karzai F, Nipp R, Naqash AR, Gulley JL, Floudas CS. Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020. J Natl Cancer Inst. 2024 Jul 1;116(7):1063-1071. doi: 10.1093/jnci/djae018. PubMed PMID: 38374401; PubMed Central PMCID: PMC11223850.

select

Victory JH, Smith EC, Ryan CE, Lambdin J, Sarvestani AL, Friedman LR, Eade AV, Larrain C, Pu T, Luberice K, Ramamoorthy B, Rainey AJ, Hannah CE, Smith KM, Mabry D, Xie C, Davis JL, Blakely AM, Gulley JL, Schlom J, Monge C, Greten TF, Hernandez JM. Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol. J Gastrointest Oncol. 2024 Jun 30;15(3):1348-1354. doi: 10.21037/jgo-24-71. Epub 2024 Jun 20. PubMed PMID: 38989414; PubMed Central PMCID: PMC11231869.

select

Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey AD Jr, Silk AW, Wargo JA. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer. 2024 Jun 19;12(6). doi: 10.1136/jitc-2024-009063. Review. PubMed PMID: 38901879; PubMed Central PMCID: PMC11191773.

select

Belue MJ, Harmon SA, Yang D, An JY, Gaur S, Law YM, Turkbey E, Xu Z, Tetreault J, Lay NS, Yilmaz EC, Phelps TE, Simon B, Lindenberg L, Mena E, Pinto PA, Bagci U, Wood BJ, Citrin DE, Dahut WL, Madan RA, Gulley JL, Xu D, Choyke PL, Turkbey B. Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study. Acad Radiol. 2024 Jun;31(6):2424-2433. doi: 10.1016/j.acra.2024.01.009. Epub 2024 Jan 22. PubMed PMID: 38262813; PubMed Central PMCID: PMC11214604.

select

Larkin RM, Lopez DC, Robbins YL, Lassoued W, Canubas K, Warner A, Karim B, Vulikh K, Hodge JW, Floudas CS, Gulley JL, Gallia GL, Allen CT, London NR Jr. Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses. J Transl Med. 2024 May 31;22(1):524. doi: 10.1186/s12967-024-05339-9. PubMed PMID: 38822345; PubMed Central PMCID: PMC11140921.

select

Xue E, Bracken-Clarke D, Iannantuono GM, Choo-Wosoba H, Gulley JL, Floudas CS. Utility of Large Language Models for Health Care Professionals and Patients in Navigating Hematopoietic Stem Cell Transplantation: Comparison of the Performance of ChatGPT-3.5, ChatGPT-4, and Bard. J Med Internet Res. 2024 May 17;26:e54758. doi: 10.2196/54758. PubMed PMID: 38758582; PubMed Central PMCID: PMC11143389.

select

Ma KC, Mena E, Lindenberg L, Lay NS, Eclarinal P, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, Madan RA, Choyke PL, Turkbey IB, Harmon SA. Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN. Oncotarget. 2024 May 7;15:288-300. doi: 10.18632/oncotarget.28583. PubMed PMID: 38712741; PubMed Central PMCID: PMC11075367.

select

Iannantuono GM, Bracken-Clarke D, Karzai F, Choo-Wosoba H, Gulley JL, Floudas CS. Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study. Oncologist. 2024 May 3;29(5):407-414. doi: 10.1093/oncolo/oyae009. PubMed PMID: 38309720; PubMed Central PMCID: PMC11067804.

select

Lopez DC, Fabian KP, Padget MR, Robbins YL, Kowalczyk JT, Lassoued W, Pastor DM, Allen CT, Gallia GL, Gulley JL, Hodge JW, London NR Jr. Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence. Front Oncol. 2024;14:1376622. doi: 10.3389/fonc.2024.1376622. eCollection 2024. PubMed PMID: 38741774; PubMed Central PMCID: PMC11089222.

select

Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-Gonzalez JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS. Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy. Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872. PubMed PMID: 37910044; PubMed Central PMCID: PMC11018485.

select

Rajan A, Abdul Sater H, Rahma O, Agajanian R, Lassoued W, Marté JL, Tsai YT, Donahue RN, Lamping E, Bailey S, Weisman A, Walter-Rodriguez B, Ito R, Vugmeyster Y, Sato M, Machl A, Schlom J, Gulley JL. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. J Immunother Cancer. 2024 Mar 13;12(3). doi: 10.1136/jitc-2023-008480. PubMed PMID: 38485188; PubMed Central PMCID: PMC10941133.

select

Minnar CM, Lui G, Gulley JL, Schlom J, Gameiro SR. Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front Oncol. 2023;13:1321318. doi: 10.3389/fonc.2023.1321318. eCollection 2023. PubMed PMID: 38260854; PubMed Central PMCID: PMC10802843.

select

Lawler M, Sullivan R, Abou-Alfa GK, McCloskey K, Keatley D, Feighan J, Dahut W, Mulroe E, Ladner R, Genead M, Lowery M, Gulley JL, Scott CJ, Longley DB, Culhane A, Gallagher WM, Orr N, Chanock SJ, Gopal S. Health diplomacy in action: The cancer legacy of the Good Friday Agreement. J Cancer Policy. 2023 Dec;38:100448. doi: 10.1016/j.jcpo.2023.100448. Epub 2023 Oct 14. PubMed PMID: 37839622.

select

Hsu J, Donahue RN, Katragadda M, Lowry J, Huang W, Srinivasan K, Guntas G, Tang J, Servattalab R, Moisan J, Tsai YT, Stoop A, Palakurthi S, Chopra R, Liu K, Wherry EJ, Su Z, Gulley JL, Bayliffe A, Schlom J. A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Sci Transl Med. 2023 Nov 29;15(724):eadi0258. doi: 10.1126/scitranslmed.adi0258. Epub 2023 Nov 29. PubMed PMID: 38019931; PubMed Central PMCID: PMC11421222.

select

Iannantuono GM, Chandran E, Floudas CS, Choo-Wosoba H, Butera G, Roselli M, Gulley JL, Karzai F. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treat Rev. 2023 Nov;120:102623. doi: 10.1016/j.ctrv.2023.102623. Epub 2023 Sep 9. PubMed PMID: 37716332; PubMed Central PMCID: PMC10591840.

select

Iannantuono GM, Bracken-Clarke D, Karzai F, Choo-Wosoba H, Gulley JL, Floudas CS. Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study. medRxiv. 2023 Oct 31;. doi: 10.1101/2023.10.31.23297825. PubMed PMID: 38076813; PubMed Central PMCID: PMC10705618.

select

Hoang DT, Dinstag G, Hermida LC, Ben-Zvi DS, Elis E, Caley K, Sammut SJ, Sinha S, Sinha N, Dampier CH, Stossel C, Patil T, Rajan A, Lassoued W, Strauss J, Bailey S, Allen C, Redman J, Beker T, Jiang P, Golan T, Wilkinson S, Sowalsky AG, Pine SR, Caldas C, Gulley JL, Aldape K, Aharonov R, Stone EA, Ruppin E. Prediction of cancer treatment response from histopathology images through imputed transcriptomics. Res Sq. 2023 Sep 15;. doi: 10.21203/rs.3.rs-3193270/v1. PubMed PMID: 37790315; PubMed Central PMCID: PMC10543028.

select

Redman JM, O'Sullivan Coyne G, Reed CT, Madan RA, Strauss J, Steinberg SJ, Marté J, Cordes L, Heery C, Gulley JL. Avelumab in Patients With Metastatic Colorectal Cancer. Oncologist. 2023 Sep 7;28(9):823-e804. doi: 10.1093/oncolo/oyad162. PubMed PMID: 37310790; PubMed Central PMCID: PMC10485289.

select

Iannantuono GM, Bracken-Clarke D, Floudas CS, Roselli M, Gulley JL, Karzai F. Applications of large language models in cancer care: current evidence and future perspectives. Front Oncol. 2023;13:1268915. doi: 10.3389/fonc.2023.1268915. eCollection 2023. Review. PubMed PMID: 37731643; PubMed Central PMCID: PMC10507617.

select

Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. Oncologist. 2023 Jul 5;28(7):642-e561. doi: 10.1093/oncolo/oyad058. PubMed PMID: 37134294; PubMed Central PMCID: PMC10322134.

select

John L, Smith H, Ilanchezhian M, Lockridge R, Reilly KM, Raygada M, Dombi E, Sandler A, Thomas BJ, Glod J, Miettinen M, Allen T, Sommer J, Levy J, Lozinsky S, Dix D, Bouffet E, MacDonald S, Mukherjee D, Snyderman CH, Rowan NR, Malyapa R, Park DM, Heery C, Gardner PA, Cote GM, Fuller S, Butman JA, Jackson S, Gulley JL, Widemann BC, Wedekind MF. The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor. Pediatr Blood Cancer. 2023 Jun 22;:e30358. doi: 10.1002/pbc.30358. [Epub ahead of print] PubMed PMID: 37347686; PubMed Central PMCID: PMC10739575.

select

Chang R, Gulley JL, Fong L. Vaccinating against cancer: getting to prime time. J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006628. Review. PubMed PMID: 37286302; PubMed Central PMCID: PMC10254974.

select

Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2023 Jun 1;133(11). doi: 10.1172/JCI172059. PubMed PMID: 37259923; PubMed Central PMCID: PMC10231984.

select

Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J. Adaptive Immunity in Genitourinary Cancers. Eur Urol Oncol. 2023 Jun;6(3):263-272. doi: 10.1016/j.euo.2023.03.002. Epub 2023 Apr 15. Review. PubMed PMID: 37069029.

select

Peer CJ, Schmidt KT, Arisa O, Richardson WJ, Paydary K, Goldstein DA, Gulley JL, Figg WD, Ratain MJ. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. J Clin Pharmacol. 2023 Jun;63(6):672-680. doi: 10.1002/jcph.2203. Epub 2023 Feb 8. PubMed PMID: 36624662; PubMed Central PMCID: PMC10175103.

select

Barcellos-Hoff MH, Gulley JL. Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy. Clin Cancer Res. 2023 Jun 1;29(11):2025-2033. doi: 10.1158/1078-0432.CCR-21-3750. PubMed PMID: 36598437; PubMed Central PMCID: PMC10238558.

select

Zhang L, Troccoli CI, Mateo-Victoriano B, Lincheta LM, Jackson E, Shu P, Plastini T, Tao W, Kwon D, Chen X, Sharma J, Jorda M, Gulley JL, Bilusic M, Lockhart AC, Beuve A, Rai P. The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance. bioRxiv. 2023 May 3;. doi: 10.1101/2023.05.03.537252. PubMed PMID: 37205442; PubMed Central PMCID: PMC10187243.

select

Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, Gourdin TS, Maio M, Dirix L, Schlom J, Donahue RN, Tsai YT, Wang X, Vugmeyster Y, Beier F, Seebeck J, Schroeder A, Chennoufi S, Gulley JL. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-005813. PubMed PMID: 37236636; PubMed Central PMCID: PMC10230972.

select

Madan RA, Redman JM, Karzai F, Dahut WL, Cordes L, Fakhrejahani F, Vu T, Sheikh N, Schlom J, Gulley JL. Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. J Immunother. 2023 May 1;46(4):145-151. doi: 10.1097/CJI.0000000000000459. Epub 2023 Feb 24. PubMed PMID: 36821354; PubMed Central PMCID: PMC10072211.